Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837419 | 1.00 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL21928925 | 0.83 | TAAR1 (0.47) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL26622163 | 0.83 | TAAR1 (0.47) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL3564528 | 0.74 | PNMT (0.54) | TAAR1IDO1AGXT | |
| SCHEMBL30837416 | 0.74 | PNMT (0.54) | TAAR1IDO1AGXT | |
| SCHEMBL3570833 | 0.74 | TAAR1 (0.50) | TAAR1IDO1MAOBTDP1CYP11B1 | |
| SCHEMBL776359 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL30837414 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL24196885 | 0.74 | CYP1A2 (0.47) | TAAR1IDO1AGXTMAOBCYP1A2 | |
| SCHEMBL4399626 | 0.74 | TAAR1 (0.74) | TAAR1IDO1AGXTMAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117778339-A | Sulfoxide reductase mutant and application thereof in preparation of chiral sulfoxide and sulfinyl ester | 遵义医科大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-117757763-A | Sulfoxide reductase mutant and application thereof in chiral sulfoxide preparation | 遵义医科大学 | 2024-03-26 | — | — | CN | disclosed |
| US-7776582-B2 | for gas chromatography; identifying an optically enhanced chiral ionic liquid (OCIL) for enantiomeric resolution | SIGMA-ALDRICH CO. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090145197-A1 | Optically Enhanced Chiral Ionic Liquids | SIGMA-ALDRICH CO. NEWCO INC. | 2009-06-11 | — | — | US | disclosed |
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | ADVANCED SEPARATION TECHNOLOGIES INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | GCG, INF2, ELOVL3 | TAAR1 1789/4885IDO1 737/4885AGXT 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.